Patient-Centric Biospecimen Collection: Meeting Rare Disease Research Challenges

Photo Credit: CDC/ Dr. M. Candler

Patient-centric research begins with the recognition that patients are partners in the research enterprise — not passive sources of samples. This partnership model emphasizes transparent communication about research goals, meaningful incorporation of patient priorities into research questions, respect for participant time and contributions, and a commitment to returning value to the community through results dissemination and therapeutic advancement.

For biospecimen collection specifically, patient-centricity shows up in practical, measurable ways:

• Logistical accessibility: participation opportunities regardless of geography, mobility limitations, or proximity to specialty centers.
• Reduced burden: convenient scheduling, home-based options, and integration with existing clinical care when feasible.
• Appropriate compensation: reflecting time and effort while reducing out-of-pocket costs and practical barriers.
• Clear informed consent: plain-language description of how samples/data will be used, privacy protections, and participant rights.
• Ongoing engagement: updates, feedback loops, and accessible study communications that build trust over time.

The Critical Role of Patient Advocacy Organizations

Patient advocacy organizations (PAGs) have become essential partners in rare disease biospecimen research. They help connect researchers with patient communities, inform research priorities, support recruitment, and ensure study design reflects lived experience. Many PAGs also invest directly in research infrastructure — registries, natural history studies, and biobanking — especially for ultra-rare conditions where traditional funding mechanisms may be limited.

Advocacy partners contribute unique expertise that materially improves biospecimen study quality:

• Endpoint relevance: identifying symptoms and daily-life impacts that standard clinical measures can miss.
• Feasibility insight: surfacing barriers (travel, scheduling, caregiver demands, confidentiality concerns) before protocols are finalized.
• Community trust: improving recruitment via known, credible channels and clear expectations.
• Communication: helping translate complex study details into accessible language.

When PAGs are integrated early — during protocol development and consent drafting — studies are more likely to achieve enrollment goals, maintain retention, and generate results that matter to patients and caregivers.

Integrating Patient-Reported Outcomes with Biospecimen Collection

Traditional biospecimen research often emphasizes laboratory endpoints (biomarkers, gene expression, metabolite patterns) without systematically capturing patient experience. For many rare diseases, patient-reported outcomes (PROs) — pain, fatigue, function, GI symptoms, sleep, and quality of life — provide essential context for interpreting molecular findings.

Integrating validated PRO instruments alongside serial biospecimen collection enables researchers to:

• Link molecular signatures to symptoms patients actually experience
• Validate whether biomarker changes correlate with meaningful outcomes
• Identify potential therapeutic targets for high-burden symptoms
• Improve endpoint selection for clinical trials (especially early-phase)

For example, correlating symptom trajectories with analytes measured in plasma, serum, and PBMCs can help reveal inflammatory, metabolic, or immunologic pathways associated with patient-relevant disease burden — especially in longitudinal designs.

Reducing Participation Burden Through Direct-to-Patient Collection

Geographic barriers are among the most persistent obstacles to rare disease research. When protocols require participants to travel to academic centers, patients in rural areas, those with limited mobility, and families facing transportation or caregiver constraints may be excluded. For rare diseases where patient populations are already small and distributed across the United States, these barriers can bias cohorts and make recruitment targets unattainable.

Direct-to-patient biospecimen collection addresses this by bringing research to participants. Mobile phlebotomy teams can collect blood-based specimens (whole blood, plasma, serum, PBMCs) and other sample types (e.g., urine) according to study protocols — eliminating travel requirements and enabling broader participation.

For pediatric populations, home-based collection can be especially impactful — reducing disruption to family schedules and improving longitudinal retention. Home collection may also decrease anxiety for participants who find clinical settings stressful.

Quality in direct-to-patient collection depends on rigorous SOPs, training, standardized kits, chain-of-custody, temperature control, and time-to-processing requirements matched to study needs. For studies requiring specialized handling (e.g., PBMC isolation windows), workflows must be designed to preserve integrity from collection through shipment to the lab.

Ethical Frameworks and Informed Consent

Ethical biospecimen research requires informed consent processes that clearly communicate research purpose, potential risks and benefits, data privacy protections, and participant rights. In rare disease studies where samples may be stored and reused, consent should appropriately describe:

• Scope of current research use vs. future research use
• Governance for future access decisions
• Whether and how re-contact may occur
• Data sharing practices and residual re-identification risk

Privacy considerations are especially important as comprehensive genomic annotation becomes more common. Genomic data and deep clinical phenotyping can increase re-identification risk, so security controls, de-identification practices, and access policies should be transparent and aligned to regulatory requirements.

Participant Compensation: Valuing Contributions and Reducing Barriers

Compensation practices should acknowledge that participation has real costs — time, effort, childcare needs, and potential lost wages — and that failure to address these costs can exclude willing participants. Ethical compensation aims to reduce barriers while avoiding undue inducement, with oversight by IRBs and ethics committees based on study burden and population vulnerability.

For direct-to-patient models, eliminating travel burden already reduces cost and stress. Compensation can then focus on participant time, effort, and any study-specific inconvenience.

Building Long-Term Research Relationships

Rare disease research increasingly benefits from sustained engagement rather than one-time collections. Natural history studies, recall-on-demand repositories, and registry-linked biobanking enable longitudinal insight — within-person comparisons, treatment response dynamics, and early biomarker discovery that cross-sectional designs often miss.

Direct-to-patient infrastructure supports these relationships by making repeat participation feasible and less disruptive, improving retention in multi-year protocols.

Returning Results and Research Findings to Participants

Patient-centric biospecimen research includes a commitment to sharing study progress and findings with the community in accessible formats. While individual-level results may not always be clinically actionable, aggregate updates help participants understand how their contributions are advancing research.

When clinically relevant or sensitive findings are possible (e.g., genetic variants with health implications), protocols should define how return of results will be handled — including clinical context, appropriate counseling, and participant preferences.

From Study Design to Receipt of Samples: Patient Partnership Throughout

True patient-centric biospecimen research integrates patient partnership from initial study conception through dissemination. Advocacy representatives can help shape research questions, identify meaningful endpoints, improve consent language, anticipate participation barriers, and support ongoing engagement.

Sanguine’s approach supports patient-centric rare disease research through direct-to-donor accessibility, integration of patient-reported outcomes, and rigorous operational quality from study design to receipt of samples. Our infrastructure is designed to support diverse rare disease programs while prioritizing participant experience, ethical excellence, and reproducible specimen quality.

---

References

1. Rare Diseases Clinical Research Network. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups. Published October 29, 2024. Accessed December 10, 2024. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups
2. IQVIA. Unlocking Clinical and Commercial Success: How PAGs Power Rare Disease Innovation. Published August 2024. Accessed December 10, 2024. Unlocking Clinical and Commercial Success: How PAGs Power Rare Disease Innovation
3. BioMarin. Patient Community Engagement. Published 2024. Accessed December 10, 2024. Patient Community Engagement
4. Emerging roles and opportunities for rare disease patient advocacy groups. SAGE Journals. Published 2023. Accessed December 10, 2024. Emerging roles and opportunities for rare disease patient advocacy groups
5. NIH. PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN). Published 2024. Accessed December 10, 2024. PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
6. EveryLife Foundation for Rare Diseases. Valuing Rare Disease Treatments in Healthcare: Real Experience and Insights from Patients and Caregivers. Published January 2024. Accessed December 10, 2024. Valuing Rare Disease Treatments in Healthcare: Real Experience and Insights from Patients and Caregivers